Sage Journals: Discover world-class research

Open access

Research article

First published 2022-4

Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective,longitudinal cohort study

Bianca Raffaelli, Maria Terhart, Lucas Hendrik Overeem [...]

Cephalalgia

Open access

Research article

First published 2022-4

Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study

Lucas Hendrik Overeem, Andreas Peikert, Maxi Dana Hofacker [...]

Cephalalgia

Open access

Research article

First published 2024-10

Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study

Paul Triller, Virginia N. Blessing, Lucas H. Overeem [...]

Cephalalgia

Free access

Research article

First published 2019-12

Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries

Eloísa Rubio-Beltrán, Alejandro Labastida-Ramírez, Kristian A Haanes [...]

Cephalalgia

Free access

Research article

First published 2020-10

Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: A case report

Sebastian Wurthmann, Steffen Nägel, Eva Hadaschik [...]

Cephalalgia

Open access

Research article

First published 2024

Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study

Hsiangkuo Yuan, Fred Cohen, Maurice T Driessen [...]

Cephalalgia Reports

Free access

Review article

First published 2019-3

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications

David W Dodick

Cephalalgia

Free access

Correction

First published 2019-7

Corrigendum: CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications

Cephalalgia

Free access

Research article

First published 2019-12

Erenumab (AMG 334),a monoclonal antagonist antibody against the canonical CGRP receptor,does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries

Lena Ohlsson, Kristian A Haanes, Erik Kronvall [...]

Cephalalgia

Free access

Editorial

First published 2019-12

Cardio- and cerebrovascular safety of erenumab,a monoclonal antibody targeting CGRP receptors – important studies on human isolated arteries

Karl Messlinger, Antoinette MaassenVanDenBrink

Cephalalgia

Search results